edrecolomab
Sign in to saveEdrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.
Research
74 papers- Edrecolomab (monoclonal antibody 17-1A).Drugs · 1998
- Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma.Critical reviews in oncology/hematology · 2001
- Technology evaluation: edrecolomab, Centocor Inc.Current opinion in molecular therapeutics · 2000
- Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.Lancet (London, England) · 2002
- Edrecolomab in the adjuvant treatment of colorectal carcinoma.Lancet (London, England) · 2003
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 1 more fact
- subject has role
- monoclonal antibody
Sources (1)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Edrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.
Preliminary studies had shown promise of a possible use in patients with stage III colorectal carcinoma (with metastasis to the lymph nodes). No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.
Excerpted from Wikipedia’s “edrecolomab” article, available under the CC BY-SA 4.0 licence.